Inhibition of TNF-α improves indomethacin-induced enteropathy in rats by modulating iNOS expression

Digestive Diseases and Sciences

Volumn 50, Issue 9, 2005, Pages 1677-1683

  Saud, B ^a   Nandi, J ^a   Ong, G ^a   Finocchiaro, S ^a   Levine, R A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Anti TNF ; Antibody; Intestinal ulceration; Nitric oxide synthase; Phosphodiesterase inhibitor

Indexed keywords

CYTOKINE; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; MYELOPEROXIDASE; NITRATE; NITRITE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; ENTEROPATHY; ENZYME ACTIVITY; ILEITIS; ILEOJEJUNITIS; INFLAMMATION; JEJUNUM; JEJUNUM DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ULCER; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DOWN-REGULATION; ILEITIS; INDOMETHACIN; INFLAMMATION; JEJUNAL DISEASES; MALE; NITRATES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; THEOPHYLLINE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 23944487810     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2914-0     Document Type: Article

References (28)

1. Komatsu M, Koboyashi D, Saito K, Furuga D, Yagihashi A, Agaake H, Tsuji N, Sakamaki S, Niitsa Y, Watanabe N: Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 47:1297-1231, 2001
2. Woywodt A, Lundwig D, Neostock P, Kruse A, Schwarting K, Jantschek G, Kirshner H, Stange EF: Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 11:267-276, 1999
3. Sartor RB: Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 106:533-539, 1994
4. Harendra de Silva DG, Mendis LN, Sheron N, Alexander GJM, Candy DCA, Chart H: Concentrations of interleukin G and tumor necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. Gut 36:194-198, 1993
5. Bertrand V, Guimband R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chanssade S, Chauvelot ML: Increase in tumor necrosis factor-α production linked to toxicity of indomethacin in the rat small intestine. Br J Pharmacol 124:1385-1394, 1998
6. Santucci L, Fiorucci S, Giansanti M, Bounori PM, DiMatteo FM, Morelli A: Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: Role of tumor necrosis factor alpha. Gut 35:909-915, 1994
7. Grisham MB, Pavlick KP, Laroux FS, Hoffnan J, Bharwani S, Wolf RE: Nitric oxide and Chronic Gut Inflammation: Controversies in inflammatory bowel disease. J Invest Med 50:272-283, 2002
8. Baeverle PA, Baltimore D: NF-KB: Ten years after. Cell 87:13-20, 1996
9. Lopez-Belmonte J, Whittle BJR, Moncada S: The action of nitric oxide donors in the prevention on induction of injury to the rat gastric mucosa. Br J Pharmacol 108:73-78, 1993
10. Pique JM, Whittle BJR, Esplagues JV: The vasodilator role of endogenous nitric oxide in the gastric microcirculation. Eur J Pharmacol 174:293-296, 1989
11. Parasher G, Frenklakh L, Goodman DR, Siddiqui T, Nandi J, Levine RA: Nitric oxide inhibitors ameliorate indomethacin induced enteropathy in rats. Dig Dis Sci 46:2536-2541, 2001
12. Miller MJS, Thompson JH, Zhang XJ, Sadowska-Krowica H, Kakkis SL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, Ye YZ, Rodi CP, Manning PT, Currie MG, Clark DA: Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 109:1475-1483, 1995
13. Miller MJS, Sandoval M: Nitric oxide III. A molecular prelude to inflammation. Am J Physiol 226 (Gastrointest Liver Physiol 39):G795-G799, 1999
14. Grisham MB, Jourd Hevil D, Wink DA: Nitric oxide: I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am J Physiol 276 (Gastrointest Liver Physiol 39):G315-0321, 1999
15. Spatafora M, Chiappara G, Merendino AM, D'Amico D, Bellia V, Bonsignore G: Theophylline suppresses the release of TNF- α by blood monocytes and alveolar macrophages. Eur Resp J 7:223-228, 1994
16. Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P, Duclos B: In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40:475-480, 1997
17. Murthy SNS, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ: Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 38:1722-1734, 1993
18. Doherty GM, Christian J, Alexander HR, Buresh CM, Norton JA: Pentoxifyline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198, 1991.
19. Nandi J, Meguid MM, Inui A, Xu Y, Makarenko IG, Tada T, Chung C: Central mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care 5:407-418, 2002
20. Davies NM, Roseth AG, Appleyaod CB, McKnight W, Soldato P. del, Calignano A, Cioino G, Wallace JL: NO-naproxen vs naproxen: ulcerogenic, analgesic and anti inflammatory effects. Aliment Pharmacol Ther 11:69-79, 1997
21. Reuter BK, Wallace JL: Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-α release. Am J Physiol 277 (Gastrointest Liver Physiol 40):G847-G854, 1999
22. Katz J, Willis J, Cooper G, Geraci K, Fiocchi C: Treatment of Crohn's disease with pentoxifylline: Lack of correlation between clinical improvement and mucosal cytokine levels. Am J Gastroenterol 94:9(abstr 270), 1999
23. Samlaska CP, Winfeld EA: Pentoxifyline. J Am Acad Derm 30:603-621, 1994
24. Spies M, Chappeli VL, Dasu MR, Herndon DN, Thompson JC, Wolf SE: Role of TNF-α in gut mucosal changes after severe burn. Am J Physiol 283 (Gastrointest Liver Physiol 46):G703-G708, 2002
25. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347:417-429, 2002
26. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97:2000-2004, 2002
27. Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, Akiba H, Yagita H, Okumura K, Watanabe M: Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis. Am J Physiol 284 (Gastrointest Liver Physiol 47):G595-G603, 2003
28. Nandi J, Saud B, Palma DT, Levine RA: 5-Aminosalicylic acid (5-ASA) improves indomethacin (INDO)-induced enteropathy by inhibiting iNOS transcription in rats. FASEB J 17:A659, 2003 (abstr)